Significance of Diabetic Kidney Disease Biomarkers in Predicting Metabolic-Associated Fatty Liver Disease

被引：3
|
作者：
Bae, Jaehyun [1 ]
Lee, Byung-Wan [2 ]
机构：
[1] Catholic Kwandong Univ, Int St Marys Hosp, Dept Internal Med, Div Endocrinol & Metab,Coll Med, Int St, Incheon 22711, South Korea
[2] Yonsei Univ, Dept Internal Med, Div Endocrinol & Metab, Coll Med, Seoul 03722, South Korea
来源：
BIOMEDICINES | 2023年 / 11卷 / 07期
关键词：
diabetic kidney disease; metabolic-associated fatty liver disease; biomarker; GELATINASE-ASSOCIATED LIPOCALIN; ACID-BINDING PROTEIN; SERUM CYSTATIN C; INSULIN-RESISTANCE; PROXIMAL TUBULE; THERAPEUTIC TARGETS; RENAL DYSFUNCTION; MOLECULE-1; KIM-1; URINARY ENZYMES; FETUIN-A;
D O I：
10.3390/biomedicines11071928
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
Metabolic-associated fatty liver disease (MAFLD) and diabetic kidney disease (DKD) share various pathophysiological factors, and epidemiological evidence suggests that these two diseases are associated. Albuminuria and the estimated glomerular filtration rate, which are conventional biomarkers of DKD, are reportedly associated with the risk or severity of MAFLD. Recently, novel DKD biomarkers reflecting renal tubular injury have been introduced to complement conventional DKD markers. In this article, we looked at previous studies that showed an association between MAFLD and DKD, and also reviewed the significance of DKD biomarkers as predictive risk factors for MAFLD.
引用
收藏
页数：13
相关论文
共 50 条
  • [21] Roles of gut microbes in metabolic-associated fatty liver disease
    Chen, Chun-Yao
    Ho, Han-Chen
    TZU CHI MEDICAL JOURNAL, 2023, 35 (04): : 279 - 289
  • [22] Metabolic-Associated Fatty Liver Disease and Diabetes A Double Whammy
    Kapoor, Nitin
    Kalra, Sanjay
    ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA, 2023, 52 (03) : 469 - 484
  • [23] Mechanisms Linking Metabolic-Associated Fatty Liver Disease (MAFLD) to Cardiovascular Disease
    Badmus, Olufunto O.
    Hinds, Terry D.
    Stec, David E.
    CURRENT HYPERTENSION REPORTS, 2023, 25 (08) : 151 - 162
  • [24] Shifts in the Bacterial Community of Supragingival Plaque Associated With Metabolic-Associated Fatty Liver Disease
    Zhao, Fen
    Dong, Ting
    Yuan, Ke-Yong
    Wang, Ning-Jian
    Xia, Fang-Zhen
    Liu, Di
    Wang, Zhi-Min
    Ma, Rui
    Lu, Ying-Li
    Huang, Zheng-Wei
    FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY, 2020, 10
  • [25] Biomarkers of diabetic kidney disease
    Colhoun, Helen M.
    Marcovecchio, M. Loredana
    DIABETOLOGIA, 2018, 61 (05) : 996 - 1011
  • [26] The Interlink Between Metabolic-Associated Fatty Liver Disease and Polycystic Ovary Syndrome
    Vidal-Cevallos, Paulina
    Mijangos-Trejo, Alejandra
    Uribe, Misael
    Tapia, Norberto Chavez
    ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA, 2023, 52 (03) : 533 - 545
  • [27] Elafibranor: A promising treatment for alcoholic liver disease, metabolic-associated fatty liver disease, and cholestatic liver disease
    Zhang, Hang
    Dong, Xuan
    Zhu, Lei
    Tang, Fu-Shan
    WORLD JOURNAL OF GASTROENTEROLOGY, 2024, 30 (40) : 4393 - 4398
  • [28] Gut microbiome composition and metabolic activity in metabolic-associated fatty liver disease
    Zhang, Daya
    Wang, Qi
    Li, Da
    Chen, Shiju
    Chen, Jinrun
    Zhu, Xuli
    Bai, Feihu
    VIRULENCE, 2025, 16 (01)
  • [29] The Epigenetic Drug Discovery Landscape for Metabolic-associated Fatty Liver Disease
    Bayoumi, Ali
    Gronbaek, Henning
    George, Jacob
    Eslam, Mohammed
    TRENDS IN GENETICS, 2020, 36 (06) : 429 - 441
  • [30] Potential Therapeutic Strategies in the Treatment of Metabolic-Associated Fatty Liver Disease
    Boldys, Aleksandra
    Buldak, Lukasz
    Maliglowka, Mateusz
    Surma, Stanislaw
    Okopien, Boguslaw
    MEDICINA-LITHUANIA, 2023, 59 (10):
12345